As of Mar 26
| -0.06 / -0.33%|
The 4 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 26.50, with a high estimate of 30.00 and a low estimate of 21.00. The median estimate represents a +44.34% increase from the last price of 18.36.
The current consensus among 5 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.